Candidate genes and potential mechanisms for chemoradiotherapy sensitivity in locally advanced rectal cancer

Li,Chunsheng; E,Changyong; Zhou,Yangyang; Yu,Wei

doi:10.3892/ol.2019.10087

Candidate genes and potential mechanisms for chemoradiotherapy sensitivity in locally advanced rectal cancer

Authors:
- Chunsheng Li
- Changyong E
- Yangyang Zhou
- Wei Yu
View Affiliations

Affiliations: Department of Gastrointestinal Colorectal and Anal Surgery, China‑Japan Union Hospital of Jilin University, Changchun, Jilin 130033, P.R. China, Department of Hepatobiliary and Pancreatic Surgery, China‑Japan Union Hospital of Jilin University, Changchun, Jilin 130033, P.R. China, Department of Neurology, The First Hospital of Jilin University, Changchun, Jilin 130021, P.R. China
Published online on: February 28, 2019 https://doi.org/10.3892/ol.2019.10087
Pages: 4494-4504
Copyright: © Li et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The aim of the present study was to investigate candidate genes for chemoradiotherapy (CRT) sensitivity in patients with locally advanced rectal cancer (LARC), and the potential mechanisms of their action. A microarray dataset (GSE98959) was obtained from the Gene Expression Omnibus database that included microRNA (miRNA, miR) expression profiling of 22 samples from patients with LARC who had received preoperative radiotherapy and chemotherapy. Of these patients, 10 responded to the treatment and 12 did not. Differentially expressed miRNAs (DEMs) were identified, followed by the construction of an miRNA‑gene network. Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway and Gene Ontology (GO) function analyses were performed on the target genes in the miRNA‑gene network. Furthermore, a protein‑protein interaction (PPI) network was constructed on the basis of the target genes, followed by GO function enrichment and KEGG pathway analysis. A total of 30 DEMs were identified between the responder and non‑responder groups. Thiamine metabolism (including miR‑371a‑3p) was the pathway with the highest enrichment of DEMs. The pathway that was most markedly enriched in the target genes of upregulated miRNAs was the pluripotency of stem cells pathway, as indicated by phosphoinositide‑4,5‑bisphosphate 3‑kinase γ (PIK3CG) and anaphase‑promoting complex subunit 2 (APC2). Pathways in cancer exhibited the highest enrichment in the set of target genes of downregulated miRNAs. KEGG pathway and GO function analysis indicated that target genes in the PPI network were enriched in the glioma pathway and assembled in the intracellular signaling cascade function, as indicated by the proto‑oncogene NRAS. miR‑371a‑3p may be a candidate miRNA for CRT sensitivity in LARC via the thiamine metabolism pathway. PIK3CG and APC2 may contribute to CRT sensitivity via signaling pathways regulating the pluripotency of stem cells. Furthermore, NRAS may serve an important role in mediating CRT sensitivity via an intracellular signaling cascade.

View Figures

View References

1	WS Jr, Tarbell NJ, Yao M, Mehta MP and Wo JY: Rectal Cancer. John Wiley & Sons, Inc. 2017.
2	Jomrich G, Silberhumer GR, Marian B, Beer A and Müllauer L: Programmed death-ligand 1 expression in rectal cancer. Eur Surg. 48:1–5. 2016. View Article : Google Scholar
3	Kim JS, Jeong SY, Shin R, Oh HK, Park KJ and Park JG: 314. Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer. Eur J Surg Oncol. 38:831. 2012. View Article : Google Scholar
4	Alderdice M, Dunne PD, Cole AJ, O'Reilly PG, McArt DG, Bingham V, Fuchs MA, McQuaid S, Loughrey MB, Murray GI, et al: Natural killer-like signature observed post therapy in locally advanced rectal cancer is a determinant of pathological response and improved survival. Mod Pathol. 30:1287–1298. 2017. View Article : Google Scholar : PubMed/NCBI
5	Sauer R, Becker H, Hohenberger W, Rödel C, Wittekind C, Fietkau R, Martus P, Tschmelitsch J, Hager E, Hess CF, et al: Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med. 351:1731–1740. 2004. View Article : Google Scholar : PubMed/NCBI
6	Cervantes A and Glynne-Jones R: Adjuvant chemotherapy for rectal cancer after preoperative radiation or chemoradiation: One size does not fit all. Ann Oncol. 26:617–619. 2015. View Article : Google Scholar : PubMed/NCBI
7	Bandres E, Agirre X, Bitarte N, Ramirez N, Zarate R, Roman-Gomez J, Prosper F and Garcia-Foncillas J: Epigenetic regulation of microRNA expression in colorectal cancer. Int J Cancer. 125:2737–2743. 2009. View Article : Google Scholar : PubMed/NCBI
8	Gaedcke J, Grade M, Søkilde R, Kaczkowski B, Difilippantonio M, Ghadimi M, Ried T and Litman T: Abstract #584: miRNA profiles predictive for response to chemoradiotherapy in rectal cancer. Cancer Res. 69:2009.
9	Svoboda M, Sana J, Fabian P, Kocakova I, Gombosova J, Nekvindova J, Radova L, Vyzula R and Slaby O: MicroRNA expression profile associated with response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer patients. Radiat Oncol. 7:1952012. View Article : Google Scholar : PubMed/NCBI
10	Drebber U, Lay M, Wedemeyer I, Vallböhmer D, Bollschweiler E, Brabender J, Mönig SP, Hölscher AH, Dienes HP and Odenthal M: Altered levels of the onco-microRNA 21 and the tumor-suppressor microRNAs 143 and 145 in advanced rectal cancer indicate successful neoadjuvant chemoradiotherapy. Int J Oncol. 39:409–415. 2011.PubMed/NCBI
11	Pradhan M, Ledford L, Pandit Y and Palakal M: Global analysis of miRNA target genes in colon rectal cancer. IEEE International Conference on Bioinformatics and Biomedicine. 341–345. 2011.
12	Ju JA, Huang CT, Lan SH, Wang TH, Lin PC, Lee JC, Tian YF and Liu HS: Characterization of a colorectal cancer migration and autophagy-related microRNA miR-338-5p and its target gene PIK3C3. Biomarkers Genomic Med. 5:74–78. 2013. View Article : Google Scholar
13	Naccarati A, Pardini B, Stefano L, Landi D, Slyskova J, Novotny J, Levy M, Polakova V, Lipska L and Vodicka P: Polymorphisms in miRNA-binding sites of nucleotide excision repair genes and colorectal cancer risk. Carcinogenesis. 33:1346–1351. 2012. View Article : Google Scholar : PubMed/NCBI
14	Conde-Muino R, Cano C, Sanchez-Martin V, Herrera A, Comino A, Medina PP Palma P and Cuadros M: Preoperative chemoradiotherapy for rectal cancer: The sensitizer role of the association between miR-375 and c-Myc. Oncotarget. 8:82294–82302. 2017. View Article : Google Scholar : PubMed/NCBI
15	Smyth GK: Limma: Linear models for microarray data. Bioinformatics and Computational Biology Solutions Using R and Bioconductor. Gentleman R, Carey VJ, Huber W, Irizarry RA and Dudoit S: Springer New York. (New York, NY). 397–420. 2005. View Article : Google Scholar
16	Benjamini Y and Hochberg Y: Controlling the false discovery rate: A practical and powerful approach to multiple testing. J R Stat Soc Series B (Methodological). 289–300. 1995. View Article : Google Scholar
17	Dweep H and Gretz N: miRWalk2.0: A comprehensive atlas of microRNA-target interactions. Nat Methods. 12:6972015. View Article : Google Scholar : PubMed/NCBI
18	Dweep H, Gretz N and Sticht C: miRWalk database for miRNA-target interactions. Methods Mol Biol. 1182:289–305. 2014. View Article : Google Scholar : PubMed/NCBI
19	Betel D, Koppal A, Agius P, Sander C and Leslie C: Comprehensive modeling of microRNA targets predicts functional non-conserved and non-canonical sites. Genome Biol. 11:R902010. View Article : Google Scholar : PubMed/NCBI
20	Wong N and Wang X: miRDB: An online resource for microRNA target prediction and functional annotations. Nucleic Acids Res. 43:D146–D152. 2015. View Article : Google Scholar : PubMed/NCBI
21	Vejnar CE and Zdobnov EM: MiRmap: Comprehensive prediction of microRNA target repression strength. Nucleic Acids Res. 40:11673–11683. 2012. View Article : Google Scholar : PubMed/NCBI
22	Rigoutsos I, Miranda K and Huynh T: rna22: A unified computational framework for discovering miRNA precursors, localizing mature miRNAs, identifying 3′UTR Target-islands and determining the targets of mature-miRNAs. IBM Corporation. (Yorktown Heights, NY, USA). 2007.
23	Agarwal V, Bell GW, Nam JW and Bartel DP: Predicting effective microRNA target sites in mammalian mRNAs. eLife. 4:e050052015. View Article : Google Scholar
24	Shannon P, Markiel A, Ozier O, Baliga NS, Wang JT, Ramage D, Amin N, Schwikowski B and Ideker T: Cytoscape: A software environment for integrated models of biomolecular interaction networks. Genome Res. 13:2498–2504. 2003. View Article : Google Scholar : PubMed/NCBI
25	Kanehisa M and Goto S: KEGG: Kyoto encyclopedia of genes and genomes. Nucleic Acids Res. 28:27–30. 2000. View Article : Google Scholar : PubMed/NCBI
26	Song W, Liu H, Wang J, Kong Y, Yin X and Zang W: MATHT: A web server for comprehensive transcriptome data analysis. J Theor Biol. 455:140–146. 2018. View Article : Google Scholar : PubMed/NCBI
27	Szklarczyk D, Franceschini A, Wyder S, Forslund K, Heller D, Huerta-Cepas J, Simonovic M, Roth A, Santos A, Tsafou KP, et al: STRING v10: Protein-protein interaction networks, integrated over the tree of life. Nucleic Acids Res. 43:D447–D452. 2015. View Article : Google Scholar : PubMed/NCBI
28	Catto JW, Alcaraz A, Bjartell AS, De Vere White R, Evans CP, Fussel S, Hamdy FC, Kallioniemi O, Mengual L, Schlomm T and Visakorpi T: MicroRNA in prostate, bladder and kidney cancer: A systematic review. Eur Urol. 59:671–681. 2011. View Article : Google Scholar : PubMed/NCBI
29	Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, Peck D, Sweet-Cordero A, Ebert BL, Mak RH, Ferrando AA, et al: MicroRNA expression profiles classify human cancers. Nature. 435:834–838. 2005. View Article : Google Scholar : PubMed/NCBI
30	Ruf CG, Dinger D, Port M, Schmelz HU, Wagner W, Matthies C, Müller-Myhsok B, Meineke V and Abend M: Small RNAs in the peripheral blood discriminate metastasized from non-metastasized seminoma. Mol Cancer. 13:472014. View Article : Google Scholar : PubMed/NCBI
31	Dieckmann KP, Radtke A, Spiekermann M, Balks T, Matthies C, Becker P, Ruf C, Oing C, Oechsle K, Bokemeyer C, et al: Serum levels of MicroRNA miR-371a-3p: A sensitive and specific new biomarker for germ cell tumours. Eur Urol. 71:213–220. 2017. View Article : Google Scholar : PubMed/NCBI
32	Spiekermann M, Belge G, Winter N, Ikogho R, Balks T, Bullerdiek J and Dieckmann KP: MicroRNA miR-371a-3p in serum of patients with germ cell tumours: Evaluations for establishing a serum biomarker. Andrology. 3:78–84. 2015. View Article : Google Scholar : PubMed/NCBI
33	Slattery ML, Potter JD, Coates A, Ma KN, Berry TD, Duncan DM and Caan BJ: Plant foods and colon cancer: An assessment of specific foods and their related nutrients (United States). Cancer Causes Control. 8:575–590. 1997. View Article : Google Scholar : PubMed/NCBI
34	Lu'o'ng KV and Nguyễn LT: The role of thiamine in cancer: Possible genetic and cellular signaling mechanisms. Cancer Genomics Proteomics. 10:169–185. 2013.PubMed/NCBI
35	Buczacki S, Davies RJ and Winton DJ: Stem cells, quiescence and rectal carcinoma: an unexplored relationship and potential therapeutic target. Br J Cancer. 105:1253–1259. 2011. View Article : Google Scholar : PubMed/NCBI
36	Mirzaei A, Tavoosidana G, Modarressi MH, Rad AA, Fazeli MS, Shirkoohi R, Tavakoli-Yaraki M and Madjd Z: Upregulation of circulating cancer stem cell marker, DCLK1 but not Lgr5, in chemoradiotherapy-treated colorectal cancer patients. Tumour Biol. 36:4801–4810. 2015. View Article : Google Scholar : PubMed/NCBI
37	Hiroishi K, Inomata M, Kashima K, Yasuda K, Shiraishi N, Yokoyama S and Kitano S: Cancer stem cell-related factors are associated with the efficacy of pre-operative chemoradiotherapy for locally advanced rectal cancer. Exp Ther Med. 2:465–470. 2011. View Article : Google Scholar : PubMed/NCBI
38	Semba S, Itoh N, Ito M, Youssef EM, Harada M, Moriya T, Kimura W and Yamakawa M: Down-regulation of PIK3CG, a catalytic subunit of phosphatidylinositol 3-OH kinase, by CpG hypermethylation in human colorectal carcinoma. Clin Cancer Res. 8:3824–3831. 2002.PubMed/NCBI
39	Jarrett CR, Blancato J, Cao T, Bressette DS, Cepeda M, Young PE, King CR and Byers SW: Human APC2 localization and allelic imbalance. Cancer Res. 61:7978–7984. 2001.PubMed/NCBI
40	Yang D, Zhang M and Gold B: Origin of somatic mutations in β-catenin versus APC in colon cancer: Random mutagenesis in animal models versus Non-random mutagenesis in humans. Chem Res Toxicol. 30:1369–1375. 2017. View Article : Google Scholar : PubMed/NCBI
41	Hao T and Brooks TA: Abstract 2110: Modulating NRAS mRNA translation by nucleic acid clamp-mediated stabilization of the 5′-UTR G-quadruplex. Cancer Res. 75:21102015. View Article : Google Scholar
42	Vaughn CP, Zobell SD, Furtado LV, Baker CL and Samowitz WS: Frequency of KRAS, BRAF, and NRAS mutations in colorectal cancer. Genes Chromosomes Cancer. 50:307–312. 2011. View Article : Google Scholar : PubMed/NCBI
43	Jauhri M, Bhatnagar A, Gupta S, Bp M, Minhas S, Shokeen Y and Aggarwal S: Prevalence and coexistence of KRAS, BRAF, PIK3CA, NRAS, TP53, and APC mutations in Indian colorectal cancer patients: Next-generation sequencing-based cohort study. Tumour Biol. 39:10104283176922652017. View Article : Google Scholar : PubMed/NCBI
44	Hsu HC, Thiam TK, Lu YJ, Yeh CY, Tsai WS, You JF, Hung HY, Tsai CN, Hsu A, Chen HC, et al: Mutations of KRAS/NRAS/BRAF predict cetuximab resistance in metastatic colorectal cancer patients. Oncotarget. 7:22257–22270. 2016. View Article : Google Scholar : PubMed/NCBI
45	Bagadi SB, Sanghvi M, Nair SB and Das BR: Combined mutational analysis of KRAS, NRAS and BRAF genes in Indian patients with colorectal carcinoma. Int J Biol Markers. 27:27–33. 2012. View Article : Google Scholar : PubMed/NCBI